heat shock protein family A (Hsp70) member 4 likeGenealiases: APG-1 · APG1 · HSPH3 · Osp94
Q-omics provides the consensus-scored HSPA4L profile across patient tissues and cancer cell-line models. HSPA4L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HSPA4L is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, HSPA4L protein abundance shows 20,306 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where HSPA4L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPA4L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPA4L survival associations across molecular data types. HSPA4L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPA4L RNA expression–survival associations across cancer types. High HSPA4L expression shows unfavorable associations in BLCA, MESO, LIHC, LUAD and LGG, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HSPA4L RNA expression.
This table summarizes HSPA4L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HSPA4L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPA4L shows lower tumor expression in THCA and BRCA and higher tumor expression in LUAD, LUSC, HNSC and COAD. The THCA box plot shows higher HSPA4L RNA expression in normal versus tumor tissue (log2 FC = −0.881, t-test p < 0.001).
This table shows molecular features associated with HSPA4L in patient tissues and cancer cell lines. In patient samples, HSPA4L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPA4L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
